Lyra therapeutics reports fourth quarter and full year 2023 financial results and provides corporate update

-- data from enlighten i pivotal phase 3 trial of lyr-210 in chronic rhinosinusitis (crs) anticipated q2 2024 -- watertown, mass., march 21, 2024 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (crs), today reported its financial results for the fourth quarter and full year ended december 31, 2023 and provided a corporate update.
LYRA Ratings Summary
LYRA Quant Ranking